Our state‑of‑the‑art Shanghai R&D and manufacturing campus spans more than 60,000 sq. ft., purpose‑built to accelerate medical device innovation.
The facility features Class 10,000 (biological and non‑biological) clean production workshops, Class 100,000 clean production areas, and multiple Class 10,000 clean laboratories—providing over 20,000 sq. ft. of certified clean space.
This advanced infrastructure enables high‑quality development, rapid iteration, and reliable large‑scale production.
By combining our in‑house R&D expertise with advanced prototyping tools and the robust supply‑chain ecosystem surrounding Shanghai, we deliver exceptionally fast development cycles.
Our teams can achieve an average prototyping turnaround of 3–30 days—accelerating innovation and enabling rapid iteration across a wide range of product complexities.
Medical device innovation demands a rare combination of clinical insight, advanced technologies, scientific discovery, regulatory expertise, and market awareness. To meet this challenge, we have assembled a multidisciplinary team of more than 110 professionals across innovation discovery, R&D, process engineering, quality control, quality systems, regulatory affairs, manufacturing, and commercialization. Together, they drive a seamless path from concept to market‑ready medical solutions.
Our independently developed digital operations platform, Synes, provides real‑time visibility and end‑to‑end traceability across the entire business process. Fully integrated with our Quality Management System (QMS), it unifies core workflows, from R&D through final delivery, ensuring consistent regulatory compliance and enabling efficientSynes, provides real‑time visibility and end‑to‑end traceability across the entire business process. Fully integrated with our Quality Management System (QMS), it unifies core workflows, from R&D through final delivery, ensuring consistent regulatory compliance and enabling efficient, high‑quality execution at every stage.
Our AI Knowledge Engine initiative began in early 2022, positioning us ahead of the industry’s generative‑AI curve. The platform integrates a proprietary innovation database that specifically connects insights across engineering, clinical, and regulatory domains, and an agent-driven interface, ensuring zero hallucination in knowledge searching and synthesis. This system strengthens our ability to identify high‑value opportunities, reduce development risks, and accelerate decision‑making. In 2026, we will introduce Automatic Knowledge Discovery, a major expansion that will further increase innovation throughput and enhance the scalability of our product pipeline.